Acadia can’t shake off its Nuplazid nightmare

Whether Acadia has a future will not become clear until the US FDA concludes a review into the safety of the group’s controversial antipsychotic, Nuplazid. While no further evidence might emerge in the meantime, investors need to be braced for volatility all the same.